César Sánchez

High Impact

Associate profesor

University of Arkansas for Medical Sciences

faculty

COM | Internal Med Hem-Onc

20 h-index 148 pubs 2,402 cited

Research Areas

Cancer Treatment and Pharmacology Cancer Immunotherapy and Biomarkers Health Disparities and Outcomes Mobile Health and mHealth Applications Genomics and Phylogenetic Studies Breast Cancer Treatment Studies Quality of Life Multiple Myeloma Research and Treatments

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

César Sánchez's research focuses on cancer treatment and patient outcomes, particularly in breast, gastric, and gastrointestinal stromal cancers. He has investigated the efficacy of therapies such as pembrolizumab in advanced gastric cancer and ripretinib in gastrointestinal stromal tumors, including analyses of circulating tumor DNA (ctDNA) as a biomarker. His work also addresses the impact of patient factors on cancer prognosis and quality of life, such as upper-limb disability and lymphedema severity in breast cancer patients, and the association of obesity with early recurrence after neoadjuvant chemotherapy.

Dr. Sánchez has explored diverse aspects of cancer care, including the co-design of mobile applications for patient engagement in reporting health experiences. His research extends to comparative profiling of circulating exosomal small RNAs in patients with tuberculosis and pulmonary adenocarcinoma. He has also examined the association between screen-detected versus symptomatic breast cancer and patient survival in a Chilean cohort, and contributed to optimizing chemotherapy scheduling processes.

With a career marked by extensive scholarship, Dr. Sánchez has amassed 148 publications and 2,402 citations, with an h-index of 20. He is recognized as a highly cited researcher and leads a research group. His collaborations include shared publications with Carlos Balmaceda.

Metrics

h-index: 20
Publications: 148
Citations: 2,402

Selected Publications

Randomized Trial Assessing Prospective Surveillance and Exercise for Preventing Breast Cancer-Related Lymphedema in High-Risk Patients (2025) DOI
Dietary Interventions for Cancer Prevention: An Update to ACS International Guidelines (2024) DOI
Hormone receptor-positive early breast cancer in young women: A comprehensive review (2024) DOI
Calorie Restriction and Time-Restricted Feeding: Effective Interventions in Overweight or Obese Patients Undergoing Radiotherapy Treatment with Curative Intent for Cancer (2024) DOI
Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines (2024) DOI
High linoleic acid levels in red blood cells predict a poor response to neoadjuvant chemotherapy in human epidermal growth factor receptor type 2-positive breast cancer patients (2024) DOI
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial (2024) DOI
Calorie Restriction and Time-Restricted Feeding: Effective Interventions in Overweight or Obese Patients Undergoing Radiotherapy Treatment with Curative Intent for Cancer (2023) DOI
Breast Cancer Screening in Latin America: The Challenge to Move from Opportunistic to Organized-Systematic Screening (2023) DOI
Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry (2023) DOI
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023) DOI
Co-design of a Mobile App for Engaging Breast Cancer Patients in Reporting Health Experiences: Qualitative Case Study (2023) DOI
An approximate dynamic programming approach to network-based scheduling of chemotherapy treatment sessions (2023) DOI
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study (2023) DOI
Upper-Limb Disability and the Severity of Lymphedema Reduce the Quality of Life of Patients with Breast Cancer-Related Lymphedema (2023) DOI

Grants & Funding

S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma SouthWest Oncology Group Principal Investigator
276212 Open-label, Multicenter Phase 2 Study Evaluating the Efficacy&Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor T-cell Therapy in Patients w/ Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy CARGO Therapeutics, Inc. Principal Investigator
276212 Open-label, Multicenter Phase 2 Study Evaluating the Efficacy&Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor T-cell Therapy in Patients w/ Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy CARGO Therapeutics, Inc. Principal Investigator